コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 PCV13 appears highly effective against invasive pneumoco
2 PCV13 effectiveness among 26 case-control sets of childr
3 PCV13 elicited significantly higher IgG responses for PC
4 PCV13 has a significant added benefit over PCV7 in reduc
5 PCV13 has brought greater benefits than we had expected
6 PCV13 immunisation provides a robust strategy for combat
7 PCV13 provides significant protection for most of the va
8 PCV13 reduced IPD across all age groups when used routin
9 PCV13 resulted in lower acquisition and prevalence of NP
10 PCV13 serotype-specific opsonophagocytic activity (OPA)
11 PCV13 serotypes 19A and 3 were still responsible for hal
12 PCV13 serotypes caused 50% of IPD cases in whites aged >
13 PCV13 significantly reduced NP acquisition of the additi
14 PCV13 vaccination of immunocompromised adults may substa
15 PCV13 was rapidly introduced into the Alaska childhood i
16 12, and 24 months after vaccination in 1006 PCV13 recipients and 1005 controls with 3 age-stratified
17 CV10) and pneumococcal conjugate vaccine 13 (PCV13), are used in childhood immunization programs worl
23 y PCV7 plus serotype 6A and the 5 additional PCV13 serotypes (5VT : 1, 3, 5, 7F, 19A) decreased by 96
24 15-0.21) for PCV7+6A serotypes, 5 additional PCV13 serotypes, and all-pneumococcal OM, respectively;
26 ion was shown for four of the six additional PCV13 serotypes (vaccine effectiveness for serotype 3 wa
27 tly reduced NP acquisition of the additional PCV13 serotypes 1, 6A, 7F, and 19A; the cross-reacting s
28 , compared to PCV7 serotypes, the additional PCV13 serotypes are more likely to cause bacteremic LRTI
34 IPD rates in both sexes, rates of IPD after PCV13 were still significantly higher in male than in fe
35 IPD incidence in the total population after PCV13's introduction, and a 71% reduction (95% CI, 62%-7
36 otypes in PCV13 declined significantly after PCV13 introduction in all ages (P </= .01), and the inci
37 red serotypes 1, 6B, 7F, and 19F and against PCV13 serotypes 6A and 19A were measured in peripheral b
39 geometric mean concentrations (GMCs) against PCV13-included serotypes 1 month after the booster dose
40 veness of two or more doses of PCV13 against PCV13-serotype invasive pneumococcal disease was 85% (95
41 n immunocompetent adults >/=65 years of age, PCV13 elicits significant increases in OPA titers and Ig
42 cant increases in antibody levels across all PCV13 serotypes (GMFR range, 2.99-23.85; 95% confidence
43 in period 1; 13.8% vs 9.7% in period 2) and PCV13-serotype colonization (8.7% vs 5.4% in period 1; 4
44 plementation of PCV7 (in September 2006) and PCV13 (in April 2010) in children aged <2 years (11 hosp
48 3 (FIMs), diphtheria, tetanus, Hib, MCC and PCV13 serotypes were compared to responses in a historic
49 and in the right leg at 3 and 4 months; and PCV13 in the left leg at 2 months, in the right leg at 4
52 the introduction of PCV13 alone or PCV10 and PCV13 with the average incidence during the preceding pe
53 t pneumococcal conjugate vaccines (PCV10 and PCV13) induce immunological memory against Streptococcus
54 the introduction of PCV13 alone or PCV10 and PCV13, the pooled IRR was 0.53 (95% CI 0.43-0.65) for in
58 res of widespread macrolide use and PCV7 and PCV13 introductions on S. pneumoniae were associated wit
61 nt pneumococcal conjugate vaccines (PCV7 and PCV13, respectively) altered pneumococcal serotype dynam
62 nt pneumococcal conjugate vaccines (PCV7 and PCV13, respectively) are highly effective in preventing
66 cted in 98 subjects (13.8%) by any test, and PCV13-associated serotype(s) were identified by UAD in 7
68 On days 0 to 1, children receiving TIV and PCV13 simultaneously had higher rates (37.6%) of fever (
71 l estimate [95% IE] 59-68) and IPD caused by PCV13 minus PCV7 serotypes declined by 93% (91-94), by J
72 ll also declined by 12-32% and IPD caused by PCV13 minus PCV7 type IPD declined by 58-72%, depending
73 n of the additional six serotypes covered by PCV13 (4.48 vs 1.40 per 100,000; IRR 0.31, 0.28-0.35).
74 rmine the prevalence of serotypes covered by PCV13 in a cohort of patients with invasive pneumococcal
78 sive pneumococcal disease and 2991 controls; PCV13 serotype cases (217 [30%]) included most commonly
84 he group of serotypes not included in either PCV13 or PPV23 were more frequently isolated in patients
85 accine (PCV7) with its 13-valent equivalent (PCV13), partly based on projections from mathematical mo
88 linical indications have decreased following PCV13 use, largely related to decreases in serotype 19A
94 cited significantly higher IgG responses for PCV13 additional serotypes and serotype 19F, and similar
99 riod, the proportion of isolates included in PCV13 (plus a related serotype) decreased significantly
100 ceptible IPD caused by serotypes included in PCV13 but not in PCV7 decreased from 6.5 to 0.5 per 100
101 ceptible IPD caused by serotypes included in PCV13 but not PCV7 were prevented among children aged <5
105 e 6C increased in PCV10 counties, but not in PCV13 counties, suggesting cross-protection with 6A, whi
106 icant decrease were serotype 19F, present in PCV13 and PCV7, and serotypes 6A and 19A, present in PCV
110 eater than for IPD due to extra serotypes in PCV13 (13v-non7v) in a similar period (IRR, 0.58; CI, .5
111 of IPD due to the additional 6 serotypes in PCV13 and to nonvaccine types (NVTs) increased in childr
112 of IPD due to the 6 additional serotypes in PCV13 declined significantly after PCV13 introduction in
113 CV7 serotypes, the 6 additional serotypes in PCV13, and NVTs were 0.3, 2.8, and 4.4 cases/100 000; th
114 gs show that for nine of the 13 serotypes in PCV13, post-booster responses in infants primed with a s
115 r dose 3 leading to pneumococcal infection), PCV13 and PPSV23 (Guillain-Barre syndrome), or PPSV23 (c
116 e and middle-income countries that introduce PCV13 can expect substantial reductions in invasive pneu
120 invasive pneumococcal disease caused by non-PCV13 serotypes increased, which suggests serotype repla
122 antibiotic-nonsusceptible IPD caused by non-PCV13 serotypes, no non-PCV13 serotype dominated among a
125 le IPD caused by non-PCV13 serotypes, no non-PCV13 serotype dominated among antibiotic-nonsusceptible
126 ldren younger than 5 years, incidence of non-PCV13 serotypes in 2013/14 was higher than in 2012/13 (a
128 the pre-PCV13 baseline, the incidence of non-PCV13 serotypes increased (incidence all ages 4.19 vs 5.
129 , and all-pneumococcal OM, respectively; non-PCV13 serotype episodes were not significantly reduced.
130 umococcal vaccine (PCV13) was high, some non-PCV13-emergent serotypes are more prevalent in immunocom
132 ing invasive pneumococcal disease due to non-PCV13 serotypes, particularly in children younger than 5
134 cells in PhtD-vaccinated adult mice, but not PCV13-vaccinated mice, caused a loss of vaccine-induced
138 In all 3 age categories, a single dose of PCV13 elicited OPA titers and IgG concentrations for all
139 igible to have received at least one dose of PCV13; cases had the same eligibility criteria with the
140 ss the effectiveness of two or more doses of PCV13 against invasive pneumococcal disease in children
141 The effectiveness of two or more doses of PCV13 against PCV13-serotype invasive pneumococcal disea
142 imate of the effectiveness of three doses of PCV13 against radiological pneumonia was an adjusted odd
143 than 5 years in NYC with 1 or more doses of PCV13 increased from 47.8% in 2010 to 89.8% in 2012.
148 We also investigated the effectiveness of PCV13 using case-control methods between Sept 12, 2011,
149 umococcal OM rates, with near-elimination of PCV13 disease, was observed shortly after PCV7/PCV13 int
155 ing a comprehensive picture of the impact of PCV13 on pneumococcal population structure and informing
157 ed double-blind trial compared the impact of PCV13 versus PCV7 on nasopharyngeal (NP) colonization an
158 es were identified after the introduction of PCV13 (0/35 [0%] before versus 9/43 [20.9%] after; P = 0
159 -May 11, 2010) and after the introduction of PCV13 (Jan 1, 2013-Dec 31, 2014), adjusting for changes
160 ach of the 4 years after the introduction of PCV13 alone or PCV10 and PCV13 with the average incidenc
162 mission before and after the introduction of PCV13 and used a negative binomial multiple regression m
163 cidence before and after the introduction of PCV13 by serotype grouping, age, and race/ethnicity.
164 quently stabilized until the introduction of PCV13 in 2010 when MR-IPD incidence decreased further fr
165 f MDR serotype 35B after the introduction of PCV13 was directly associated with the emergence of ST15
167 d dramatically following the introduction of PCV13, with reductions among all age and racial/ethnic g
179 infants given a reduced priming schedule of PCV13 (ie, a 1 + 1 schedule) versus the current 2 + 1 sc
181 We aimed to assess the effect of use of PCV13 in children on IPD in children and adults in the U
184 e given two priming doses of PCV7 (n=126) or PCV13 (n=237) and opsonophagocytic antibody titre from a
188 nts were randomized (1:1) to receive PCV7 or PCV13 at ages 2, 4, 6, and 12 months; NP swabs were coll
191 (PCV7) from 2005, replaced by 13-valent PCV (PCV13) in 2011, uniquely among high-income countries giv
193 ns of 7-valent PCV (PCV7) and 13-valent PCV (PCV13) were associated with declines in IPD rates in bot
196 We aimed at assessing the impact of PCV7/PCV13 sequential introduction on pneumococcal and overal
208 creases in genetic diversity were noted post-PCV13, and lineages associated with antimicrobial nonsus
211 m 21.0 cases per 100000 (2007-2009 mean) pre-PCV13 to 6.4 cases per 100000 (2011-2012 mean) post-PCV1
212 Patients were divided into 3 subgroups: pre-PCV13 (2007-2009), transitional year (2010), and post-PC
214 13/14 decreased by 32% compared with the pre-PCV13 baseline (incidence 10.14 per 100,000 in 2008-10 v
218 hy infants were randomly assigned to receive PCV13 (n = 932) or PCV7 (n = 934) at ages 2, 4, 6, or 12
219 ants were randomly assigned (1:1) to receive PCV13 at 2, 4, and 12 months (2 + 1 schedule) or 3 and 1
220 were randomly assigned (1:1:1:1) to receive PCV13 either at ages 2, 4, and 6 months (2-4-6); at ages
222 duction of a vaccine targeting 13 serotypes (PCV13) in 2010 has led to concern that this scenario wil
223 pneumococcal disease included in the study, PCV13 vaccine effectiveness after two doses before age 1
224 INTERPRETATION: Our results indicate that PCV13 in a 2 + 1 schedule is effective for preventing va
227 nes transmission, these results suggest that PCV13 will provide protection against ANSP disease that
230 2013, were classified as being caused by the PCV13 serotypes against which PCV7 has no effect (PCV13
232 es with differing PCV schedules and from the PCV13 era are needed to inform vaccination strategies fo
233 disease caused by serotypes included in the PCV13 decreased by 82.5% (95% CI, -90.0% to -69.3%), inc
234 ococcal disease occurred in 7 persons in the PCV13 group and 28 persons in the placebo group (vaccine
235 ired pneumonia occurred in 33 persons in the PCV13 group and 60 persons in the placebo group (vaccine
236 red pneumonia occurred in 747 persons in the PCV13 group and 787 persons in placebo group (vaccine ef
237 ired pneumonia occurred in 49 persons in the PCV13 group and 90 persons in the placebo group (vaccine
238 antibiotics) was significantly lower in the PCV13 group compared with the PCV7 group; the main serot
239 quencies of PCs and Bmems were higher in the PCV13 group, pre- and postbooster, except for PC frequen
241 by PCV7 + 6A serotypes was decreased; in the PCV13 period, 5VT OM rates decreased, along with an addi
243 crease continues, the maximum benefit of the PCV13 programme in children might already have been achi
244 dence interval) comparing the pre-PCV to the PCV13 period were 0.02 (0.01-0.04), 0.12 (0.08-0.20), an
247 d serious adverse events possibly related to PCV13 (facial diplegia, injection-site erythema and pyre
251 he 13-valent pneumococcal conjugate vaccine (PCV13) against first episodes of vaccine-type community-
252 se 13-valent pneumococcal conjugate vaccine (PCV13) alone and four use the ten-valent PCV (PCV10) and
253 a 13-valent pneumococcal conjugate vaccine (PCV13) and PPSV23 (23-valent polysaccharide vaccine) for
254 of 13-valent pneumococcal conjugate vaccine (PCV13) at 1-month intervals, a fourth dose 6 months late
255 age, and the pneumococcal conjugate vaccine (PCV13) at 2, 4, and 12 months, all administered to the r
257 of 13-valent pneumococcal conjugate vaccine (PCV13) compared with 23-valent pneumococcal polysacchari
258 he 13-valent pneumococcal conjugate vaccine (PCV13) has recently been approved for use in immunocompr
259 13-valent polysaccharide conjugate vaccine (PCV13) in preventing first episodes of vaccine-type stra
262 of 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal meningitis (PM) in US children is
264 he 13-valent pneumococcal conjugate vaccine (PCV13) protects against key serotypes that increased aft
265 a 13-valent pneumococcal conjugate vaccine (PCV13) replaced a 7-valent vaccine (PCV7) that contained
267 0, 13-valent pneumococcal conjugate vaccine (PCV13) replaced the seven-valent vaccine in the USA.
269 he 13-valent pneumococcal conjugate vaccine (PCV13) was designed to include disease-causing serotypes
270 he 13-valent pneumococcal conjugate vaccine (PCV13) was inferred before licensure from an aggregate c
271 a 13-valent pneumococcal conjugate vaccine (PCV13) was introduced to the routine childhood immunizat
273 0, 13-valent pneumococcal conjugate vaccine (PCV13) was licensed and recommended in the USA for preve
274 he 13-valent pneumococcal conjugate vaccine (PCV13) was licensed to replace the 7-valent pneumococcal
275 luded in the pneumococcal conjugate vaccine (PCV13) was recently reported as a useful diagnostic tool
276 of 13-valent pneumococcal conjugate vaccine (PCV13) was recommended for immunocompromised adults in t
277 he 13-valent pneumococcal conjugate vaccine (PCV13), ST diversity increased in children <5 years (D,
282 he 13-valent conjugate pneumococcal vaccine (PCV13) was high, some non-PCV13-emergent serotypes are m
283 -3-4 months, 13-valent pneumococcal vaccine (PCV13, CRM-conjugated) at 2-4 months and 1 or 2 meningoc
289 ausing IPD in immunocompromised persons were PCV13 serotypes and 27% were PPV23/not PCV13 serotypes.
291 with high HIV prevalence was associated with PCV13-serotype colonization reduction, including among u
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。